EP Patent

EP4009962A1 — Compositions of trofinetide

Assigned to Neuren Pharmaceuticals Ltd New Zealand · Expires 2022-06-15 · 4y expired

What this patent protects

This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this d…

USPTO Abstract

This disclosure describes compounds of Formula (I), stereoisomers, side compounds thereof, pharmaceutical compositions and methods of manufacturing such compounds, using silylation reagents and producing compositions and products made using such methods. More particularly, this disclosure describes manufacture of trofinetide and side products, compositions and products containing such compounds, for pharmaceutical uses to treat neurodegenerative or neurodevelopmental disorders.

Drugs covered by this patent

Patent Metadata

Patent number
EP4009962A1
Jurisdiction
EP
Classification
—
Expires
2022-06-15
Drug substance claim
No
Drug product claim
No
Assignee
Neuren Pharmaceuticals Ltd New Zealand
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.